Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world efficacy and safety of Iparomlimab and Tuvonralimab in advanced solid tumors after standard therapy failure
ChiCTR2500111041Phase 4Not yet recruiting
- Sponsor
- First Hospital of Nanping
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab + tuvonralimab in Non-hematologic malignancy, bronchial carcinoma, liver cancer and 9 more, sponsored by First Hospital of Nanping. Primary endpoint: Health-related quality of life. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
Non-hematologic malignancybronchial carcinomaliver cancergastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500111041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111041.